Breaking NewsEconomicsmanufacturingOpinionPolicyProtectionismtariffsTrade

Three Big Reasons to Doubt Trump’s Tariff-Driven Investment ‘Boom’

With President Donald Trump’s latest tariffs emerging any minute now, I’ll save my review of their problems for another time. (Spoiler: You can bet your life savings that they’re not actually “reciprocal tariffs.”) Today we’ll instead dig into one of the administration’s most common defenses for these and other new import taxes—that they’ll supercharge domestic manufacturing investment. On the surface, the Trump team and other tariff defenders would appear to have a point: As they’re so fond of noting, multinational corporations have announced more than $1 trillion in new U.S. investments since Trump took office—announcements most often accompanied by a big press conference with Trump or another government official tying the spending directly to U.S. tariff policy. Thus, so the theory goes, the tariffs are doing exactly as Trump promised—bringing manufacturing “back” to America—and will be a net winner for the U.S. economy in the long term, even if there are some, ahem, short-term bumps along the way.

Dig a little deeper, however, and the “investment boom” thesis is riddled with problems (beyond the fact that the U.S. is already a global manufacturing powerhouse, I mean)—ones that show Trump’s tariffs to likely reduce, not increase, U.S. business investment in the coming years, especially as compared to a reasonable, freer market alternative.

How Much New Investment Are We Really Getting?

The most obvious problem is that, much like we saw during the “Bidenomics” era, it’s uncertain how much new manufacturing investment the tariffs are truly inducing. As detailed in an excellent Wall Street Journal analysis from late February, several companies have included in their big announcements “previously planned spending or developments already under way.” Most notably, Apple’s much-ballyhooed promise to spend $500 billion on factories, artificial intelligence initiatives, and more was only “slightly ahead of the company’s recent four-year pace, and the spending pledge is roughly on track with its recent investments.” Only a sliver of the promised spending, moreover, was devoted to manufacturing operations that might be affected by tariffs (and even that promise is unclear). Another $500 billion promise from OpenAI, Oracle, and Softbank “includes projects the firms initiated during the Biden administration.” Elsewhere, we see that Eli Lilly’s $27 billion is only a smidge above the $23 billion it spent here since 2020 and includes a facility in North Carolina that just recently opened. (Contra what you might hear, pharma companies have been investing in the United States like crazy in the last few years.)

Source link

Related Posts

1 of 37